Volume interpolated breathhold examination (VIBE) and software-assisted MR-guided RFA for the treatment of malignant liver tumors: Initial clinical results

Diethard Schmidt1,2, Andreas Weihusen2,2, Stephan Clasen2, Hans Jörg Rempp2, Christina Schraml2, Andreas Boss1, Fritz Schick4, Claus D Claussen2, and Philippe L Pereira5

1 Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Kanton Zurich, Switzerland, 2 Diagnostic and Interventional Radiology, University Hospital Tubingen, Tubingen, Baden-Württemberg, Germany, 3 Computing imaging, FraunhoferMevis, Bremen, Germany, 4 Section for experimental radiology, University Hospital Tubingen, Tubingen, Baden-Württemberg, Germany, 5 Radiology, SLK-Kliniken, Heilbronn, Baden-Württemberg, Germany

TARGET AUDIENCE
Radiologists interested in MR guided radiofrequency ablation and computer aided therapy.

PURPOSE
To evaluate feasibility and effectivity of software-assisted monitoring of MR guided Radiofrequency ablation (RFA) of malignant liver tumors.

METHODS
MR-guided RFA of n=10 primary and n=18 secondary malignant liver tumors was performed for n=20 patients in an interventional MR unit (MagnetomEspree 1.5T, Siemens Medical Solutions, Forchheim). The tumor size was between 10 and 60 mm. Monopolar and bipolar internally-cooled MR compatible RF electrodes were used (Valleylab,Cool-tip, Burlington, MA and Celon AG, ProSurge, Teltow). Therapy monitoring was assisted by a software comparing tumor and tumor ablation state until complete tumor destruction within a given safety margin of 1 cm (MeVisSafir, FraunhoferMevis, Bremen). Therefore MR data were immediately transferred via DICOM to a MeVis workstation.

RESULTS
MR-guided RF ablation by using MeVisSafir was technically successful in 20/20 (100%) patients as assessed at the end of each session. Complete coagulation was intended in 27/28 tumors by using the software-assistant. To achieve complete coagulation 1/28 tumors required a second session. MeVisSafir was able to monitor the extent of coagulation necrosis and to determine the safety margin. Furthermore, it was supportive in guiding overlapping ablations for complete tumor coagulation for larger liver tumors (>30mm). (Fig. 1-3)

DISCUSSION
The robustness of the manually segmentation and registration has shown good results for the therapy monitoring of MR guided RFA of malignant liver tumors in combination with VIBE. But, the one-click segmentation has to be improved to reduce the duration of the analysis process until you can redo another overlapping ablation step especially for a large tumors. Further clinical evaluation is needed to have long term results for complete ablation. This may be useful to evaluate the accuracy of the registration because of a correct safety margin and possible variations of a determined safety margin of 1 cm in case of lower image quality. The software assistant is helpful for planning, navigation and assessment of MR guided tumor ablation. Additional information about temperature, e.g. with temperature sensitive sequences during RFA could be integrated for the assessment. Furthermore, a simulation of ablation for each tumor entity as a pre-interventional planning process is a future step to improve the clinical safety and outcome of MR-guided RFA of large malignant liver tumors.

CONCLUSION
Software-assisted MR-guided RFA of liver malignancies is feasible, safe and effective for larger malignant liver tumors.